Alternative Data for Healthcare Investors (Part III): Clinical Trial Datasets
Following on from Part II in our healthcare series, which explored the application of machine-learning models to generate phase transition and approval predictions, we provide our view on the alternative datasets that pharma and biotech investors can use to augment their R&D pipeline analysis.